Bicycle Therapeutics PLC
BCYC7.160USD
0.000
Cierre 09/18, 16:00（ET）Cotizaciones retrasadas 15 min
495.86MCap. mercado
PérdidaP/E TTM
Más Datos de Bicycle Therapeutics PLC Compañía
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.
Información de la empresa
Símbolo de cotizaciónBCYC
Nombre de la empresaBicycle Therapeutics PLC
Fecha de salida a bolsaMay 23, 2019
Director ejecutivoDr. Kevin Lee, Ph.D.
Número de empleados305
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 23
DirecciónBlocks A & B, Portway Building
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited Kingdom
Código postalCB21 6GS
Teléfono11441223261503
Sitio Webhttps://www.bicycletherapeutics.com/
Símbolo de cotizaciónBCYC
Fecha de salida a bolsaMay 23, 2019
Director ejecutivoDr. Kevin Lee, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
275.59K
-23.43%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
72.92K
+73.03%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
25.33K
-65.69%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
18.31K
+49.49%
Charles Swanton
Charles Swanton
Independent Director
Independent Director
--
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
--
--
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Independent Director
Independent Director
--
--
Mr. Eric Westin, M.D.
Mr. Eric Westin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephen Sands
Mr. Stephen Sands
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
275.59K
-23.43%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
72.92K
+73.03%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
25.33K
-65.69%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
18.31K
+49.49%
Charles Swanton
Charles Swanton
Independent Director
Independent Director
--
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Baker Bros. Advisors LP
21.83%
Forbion Capital Partners
6.92%
Armistice Capital LLC
5.61%
Westfield Capital Management Company, L.P.
5.58%
Invus Public Equities Advisors, LLC
4.04%
Otro
56.02%
Accionistas
Accionistas
Proporción
Baker Bros. Advisors LP
21.83%
Forbion Capital Partners
6.92%
Armistice Capital LLC
5.61%
Westfield Capital Management Company, L.P.
5.58%
Invus Public Equities Advisors, LLC
4.04%
Otro
56.02%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
46.70%
Investment Advisor
16.54%
Investment Advisor/Hedge Fund
13.13%
Venture Capital
7.06%
Research Firm
4.64%
Individual Investor
1.60%
Pension Fund
0.24%
Family Office
0.05%
Otro
10.05%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
261
46.21M
95.43%
-15.11M
2025Q1
263
46.04M
96.46%
-15.64M
2024Q4
263
44.84M
86.26%
-16.34M
2024Q3
260
44.49M
67.19%
-14.65M
2024Q2
252
44.12M
95.17%
-7.15M
2024Q1
268
34.84M
83.52%
-13.88M
2023Q4
272
34.95M
93.64%
-12.28M
2023Q3
272
41.70M
105.20%
-747.70K
2023Q2
255
34.13M
112.16%
-8.01M
2023Q1
245
32.53M
108.64%
-4.04M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Baker Bros. Advisors LP
10.89M
22.79%
-8.80K
-0.08%
Mar 31, 2025
Forbion Capital Partners
3.45M
7.23%
--
--
Mar 31, 2025
Armistice Capital LLC
2.67M
5.59%
+476.00K
+21.68%
Mar 31, 2025
Westfield Capital Management Company, L.P.
2.66M
5.56%
+46.97K
+1.80%
Mar 31, 2025
Invus Public Equities Advisors, LLC
1.81M
3.8%
-26.65K
-1.45%
Mar 31, 2025
Point72 Asset Management, L.P.
3.69M
7.73%
-862.83K
-18.94%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.54M
3.22%
-48.54K
-3.06%
Mar 31, 2025
Candriam Luxembourg S.A.
1.21M
2.53%
-20.80K
-1.69%
May 31, 2025
Long Focus Capital Management LLC
1.29M
2.71%
+750.66K
+138.22%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
